Trityl candesartanCAS# 139481-72-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 139481-72-4 | SDF | Download SDF |
| PubChem ID | 10312563 | Appearance | Powder |
| Formula | C43H34N6O3 | M.Wt | 682.8 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-ethoxy-3-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid | ||
| SMILES | CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=NN5C(C6=CC=CC=C6)(C7=CC=CC=C7)C8=CC=CC=C8)C(=O)O | ||
| Standard InChIKey | VBMKOTRJWPIKMG-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C43H34N6O3/c1-2-52-42-44-38-24-14-23-37(41(50)51)39(38)48(42)29-30-25-27-31(28-26-30)35-21-12-13-22-36(35)40-45-46-47-49(40)43(32-15-6-3-7-16-32,33-17-8-4-9-18-33)34-19-10-5-11-20-34/h3-28H,2,29H2,1H3,(H,50,51) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Trityl candesartan Dilution Calculator
Trityl candesartan Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.4646 mL | 7.3228 mL | 14.6456 mL | 29.2912 mL | 36.6139 mL |
| 5 mM | 0.2929 mL | 1.4646 mL | 2.9291 mL | 5.8582 mL | 7.3228 mL |
| 10 mM | 0.1465 mL | 0.7323 mL | 1.4646 mL | 2.9291 mL | 3.6614 mL |
| 50 mM | 0.0293 mL | 0.1465 mL | 0.2929 mL | 0.5858 mL | 0.7323 mL |
| 100 mM | 0.0146 mL | 0.0732 mL | 0.1465 mL | 0.2929 mL | 0.3661 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Candesartan methyl ester
Catalog No.:BCC8902
CAS No.:139481-69-9
- Candesartan
Catalog No.:BCC2558
CAS No.:139481-59-7
- Candesartan ethyl ester
Catalog No.:BCC8901
CAS No.:139481-58-6
- Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate
Catalog No.:BCC9032
CAS No.:139481-44-0
- Ethyl 2-ethoxy-1-[(2'-cyanobiphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylate
Catalog No.:BCC8970
CAS No.:139481-41-7
- Methyl 2-(((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)amino)-3-nitrobenzoate
Catalog No.:BCC9033
CAS No.:139481-28-0
- 6-O-apiosyl-5-O-Methylvisammioside
Catalog No.:BCN7858
CAS No.:139446-82-5
- Boc-Cysteinol(Bzl)
Catalog No.:BCC3043
CAS No.:139428-96-9
- 8alpha-Hydroxyhirsutinolide
Catalog No.:BCN7111
CAS No.:1394156-45-6
- GNE-317
Catalog No.:BCC5655
CAS No.:1394076-92-6
- Tiotropium Bromide hydrate
Catalog No.:BCC4585
CAS No.:139404-48-1
- Guan-fu base A
Catalog No.:BCN8491
CAS No.:1394-48-5
- GSK J5
Catalog No.:BCC6264
CAS No.:1394854-51-3
- GSK J2
Catalog No.:BCC6263
CAS No.:1394854-52-4
- MS436
Catalog No.:BCC4037
CAS No.:1395084-25-9
- Buddlejasaponin IV
Catalog No.:BCN5344
CAS No.:139523-30-1
- 2-(7-Methoxy-1-naphthyl)ethylamine hydrochloride
Catalog No.:BCN1574
CAS No.:139525-77-2
- Fmoc-Leu-ol
Catalog No.:BCC2582
CAS No.:139551-83-0
- Cannabidiol
Catalog No.:BCN6208
CAS No.:13956-29-1
- Lycoclavanol
Catalog No.:BCN6209
CAS No.:13956-51-9
- Serratriol
Catalog No.:BCN6210
CAS No.:13956-52-0
- Epicannabidiol hydrate
Catalog No.:BCN6207
CAS No.:139561-95-8
- 3-Bromoisonicotinic Acid
Catalog No.:BCC8368
CAS No.:13959-02-9
- Purotoxin 1
Catalog No.:BCC6333
CAS No.:1396322-38-5
Improvement of the antihypertensive capacity of candesartan and trityl candesartan by their SOD mimetic copper(II) complexes.[Pubmed:23501135]
J Inorg Biochem. 2013 Jun;123:23-33.
Two new complexes [Cu(Cand)(H2O)4] [1] and [Cu2(TCand)4(H2O)2].4H2O [2] (Cand = candesartan; TCand = Trityl candesartan) have been synthesized and thoroughly characterized. The FTIR, Raman, EPR and diffuse reflectance spectra of the solid compounds show a dimeric complex for [2] with carboxylate bridging of the type found in copper(II) acetate. Both elemental analysis and thermal measurements allow the determination of the total stoichiometries of both complexes. The stability measurements show that the compounds are stable in ethanolic solutions at least for 1h, while the preservation of the overall stochiometry for both species in solution has been determined by spectrophotometric titrations. By metal complexation the absence of antioxidant behavior of both sartans has been improved. Complexes [1] and [2] are strong superoxidedismutase mimetic compounds and complex [2] also behaves as a peroxyl radical scavenger. Furthermore, this higher antioxidant activity works in parallel with the improvement of the expansive activity over the angiotensin II-induced contracted human mesangial cells. These new complexes exhibit even higher efficiency as drugs in comparison with the free non-complexed medication with increased antioxidant ability expressing higher capacity to block the angiotensin II contractile effect. This study provides a new insight into the development of copper(II) complexes as potential drugs.
